Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 11;40(22):2993-2998.
doi: 10.1016/j.vaccine.2022.04.006. Epub 2022 Apr 8.

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

Francisco Belda  1 , Oscar Mora  2 , Monica Lopez Martinez  3 , Nerea Torres  3 , Ana Vivanco  3 , Rebecca Christie  4 , Michael Crowley  4
Affiliations

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

Francisco Belda et al. Vaccine. .

Abstract

Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from healthcare workers with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed a significantly enhanced response to the first vaccination. In older subjects, lower immunological responses to the first injection were observed, which were overcome by the second injection. All subjects in the study were positive for anti-SARS-CoV-2 IgG after the second dose of vaccine.

Keywords: COVID-19; Immunity; Immunoglobulins; SARS-CoV-2; Seroconversion panel; mRNA-1273 vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francisco Belda, Oscar Mora, Monica Lopez Martinez and Nerea Torres are employees of Grifols. Rebecca Christie and Michael Crowlet are employees of Access Biologicals..

Figures

Fig. 1A
Fig. 1A
Antibody responses (IgG) in a seroconversion panel (Panel G) of 15 subjects before and after vaccination with two doses of the mRNA-1273 SARS-CoV-2 vaccine. These results were obtained using a chemiluminescent immunoassay (CLIA). Responses ≥15.0 units were considered positive (cutoff).
Fig. 1B
Fig. 1B
Antibody responses (IgG) in Panel G before and after vaccination. These results were obtained using an enzyme-linked immunosorbent assay (ELISA). S/CO = signal-to-cutoff values. Responses ≥1.1 S/CO were considered positive.
Fig. 1c
Fig. 1c
Antibody responses (IgG) in a seroconversion panel (Panel H) of 30 subjects before and after vaccination. These results were obtained using a CLIA. (AU/mL) Arbitrary Unit. Responses ≥15.0 (AU/mL) were considered positive (cutoff). The first point shows the results from samples collected prior to the first vaccination. The middle point shows the results from samples collected after the first vaccination and prior to the second vaccination. The third point shows the results from samples collected after the second vaccination. The dashed lines correspond to the convalescent participants, while the solid lines correspond to the naïve participants.
Fig. 2
Fig. 2
Comparison of antibody responses between naïve subject versus COVID-19 convalescent subjects prior to and after vaccination. Antibody responses were measured in samples collected prior to the first vaccination, after the first vaccination and prior to the second vaccination and after the second vaccination with the mRNA-1273 SARS-CoV-2 vaccine (Moderna, Cambridge, MA, USA). These results were obtained using a chemiluminescent immunoassay (Diasorin, Inc., Saluggia, Italy). (AU/mL) Arbitrary Unit. Responses ≥15.0 (AU/mL) were considered positive; values greater than the assay range (up to 400 AU/mL) were recorded as 400 AU/mL due to the upper limit of detection. Significant differences were seen between naïve and convalescent subjects in pre-vaccine and post-vaccine: first dose samples (p < 0.0001).
See this image and copyright information in PMC

References

    1. Johns Hopkins University Center for Systems Science and Engineering. COVID-19 Dashboard. Baltimore, MD: Johns Hopkins University Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/. [accessed 10 February 2022].
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. - PMC - PubMed
    1. Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383(25):2439–2450. - PMC - PubMed
    1. Diasorin SpA. Liaison SARS-CoV-2 S1/S2 IgG: The full automated serology test for the detection of SARS-CoV-2 IgG antibodies. Available at: https://www.diasorin.com/sites/default/files/allegati/liaisonr_sars-cov-.... [accessed 5 January 2022].
    1. Lopez Martinez M., Ruiz-Arguello B., Torres N., Catarino S., Apraiz I., Maguregui A., et al. Anti-SARS-CoV-2 (immunoglobulin G) ELISA kit, a sensitive and specific assay for the detection of human anti-SARS-CoV-2 immunoglobulin G antibodies. Vox Sang. 2020;115(suppl 1):387.

Publication types